B-cell profile, B-cell activating factor concentration and IgG levels in human cutaneous and mucosal leishmaniasis.
Adolescent
Adult
Aged
B-Cell Activating Factor
/ metabolism
B-Cell Activation Factor Receptor
/ metabolism
B-Lymphocytes
/ immunology
Cytokines
/ metabolism
Female
Humans
Immunoglobulin G
/ immunology
Leishmaniasis, Cutaneous
/ immunology
Leishmaniasis, Mucocutaneous
/ immunology
Male
Middle Aged
Young Adult
B lymphocytes
B-cell activating factor
cutaneous leishmaniasis
hypergammaglobulinemia
interferon-gamma
interleukin-6
mucocutaneous leishmaniasis
Journal
Parasite immunology
ISSN: 1365-3024
Titre abrégé: Parasite Immunol
Pays: England
ID NLM: 7910948
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
03
10
2019
revised:
28
04
2020
accepted:
19
05
2020
pubmed:
28
5
2020
medline:
18
11
2020
entrez:
28
5
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate characteristics of B cells in human tegumentary leismaniasis (TL) analysing cutaneous leishmaniasis (CL), most prevalent form and mucosal leishmaniasis (ML), aggressive form characterized by the destruction of the oral-nasal-pharyngeal cavities. By flow cytometry analysis, we found decreased percentages of non-class-switched memory B cells in TL with the degree of the loss related to clinical severity. Using commercial ELISA, we reported high levels of B-cell activating factor (BAFF) and IgG preferentially in aggressive CL and markedly in ML together with decreased BAFF receptors in the latter. We also found lower levels of BAFF after clinical recovery suggesting a relation between BAFF and disease activity. Mucosal leishmaniasis history of therapeutic failure presented high levels of BAFF accompanied by detectable concentrations of IFN-γ and IL-6 (assayed by commercial ELISA and cytometric bead arrays respectively), cytokines involved in exaggerated inflammatory responses and tissue damage in TL. We demonstrate B-cell disturbances in TL with the degree of the alterations related to clinical severity. We suggest a relation between excess of BAFF and disease activity and point towards a possible implication of BAFF in the inflammatory phenomenon of ML.
Substances chimiques
B-Cell Activating Factor
0
B-Cell Activation Factor Receptor
0
Cytokines
0
Immunoglobulin G
0
TNFRSF13C protein, human
0
TNFSF13B protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12759Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Silva-Barrios S, Charpentier T, Stäger S. The deadly dance of B cells with trypanosomatids. Trends Parasitol. 2018;34(2):155-171.
Gibson-Corley KN, Boggiatto PM, Bockenstedt MM, Petersen CA, Waldschmidt TJ, Jones DE. Promotion of a functional B cell germinal center response after leishmania species co-infection is associated with lesion resolution. AJPA. 2012;180(5):2009-2017.
Wanasen N, Xin L, Soong L. Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection. Int J Parasitol. 2008;38:417-429.
Shi Y, Agematsu K, Ochs HD, Sugane K. Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol. 2003;108(2):128-137.
Kiyama K, Kawabata D, Hosono Y, et al. Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res Ther. 2012;14(2):1-8.
Mackay F, Sierro F, Grey ST, Gordon TP. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun. 2005;8:243-265.
Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol. 2006;18(5):305-317.
Fontaine J, Chagnon-Choquet J, Valcke HS, Poudrier J, Roger M. High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood. 2011;117(1):145-155.
Scholzen A, Teirlinck AC, Bijker EM, et al. BAFF and BAFF receptor levels correlate with B cell subset activation and redistribution in controlled human malaria infection. J Immunol. 2014;192(8):3719-3729.
Portugal S, Tipton CM, Sohn H, et al. Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife. 2015; 4:1-21.
Borhis G, Trovato M, Chaoul N, Ibrahim HM, Richard Y. B-cell-activating factor and the B-cell compartment in HIV/SIV infection. Front Immunol. 2017;8:1338.
Goto Y, Omachi S, Sanjoba C, Matsumoto Y. Short report: elevation of serum B-cell activating factor levels during visceral leishmaniasis. Am J Trop Med Hyg. 2014;91(5):912-914.
David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009;22(6):491-502.
Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. 2010;8(4):419-433.
Barrio A, Mora MC, Ramos F, Moreno S, Samson R, Basombrío MA. Short report: use of kDNA-based polymerase chain reaction as a sensitive and differentially diagnostic method of American tegumentary leishmaniasis in disease-endemic areas of northern Argentina. Am J Trop Med Hyg. 2007;77(4):636-639.
Barrio A, García Bustos MF, Mora MC, Parodi C, Ramos F, Moreno S. Identificación por PS-PCR de especies de Leishmania y su correlación con características clínicas, epidemiológicas y terapéuticas en Salta, Argentina. Rev Argentina Salud Pública. 2009;1(1):30-33.
Parodi C, García Bustos MF, Barrio A, et al. American tegumentary leishmaniasis: T-cell differentiation profile of cutaneous and mucosal forms-co-infection with Trypanosoma cruzi. Med Microbiol Immunol. 2016;205(4):353-369.
Van der Poll T, Zijlstra EE, Mevissen M. Interleukin 6 during active visceral leishmaniasis and after treatment. Clin Immunol Immunopathol. 1995;77(1):111-114.
Palazzi C, Buskila D, Angelo SD, Amico ED, Olivieri I. Autoimmunity reviews autoantibodies in patients with chronic hepatitis C virus infection : pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev. 2012;11(9):659-663.
García Bustos MF, González Prieto G, Ramos F, et al. Clinical and epidemiological features of leishmaniasis in northwestern-Argentina through a retrospective analysis of recent cases. Acta Trop. 2016;154:125-132.
Asito AS, Piriou E, Jura WG, et al. Suppression of circulating IgD+CD27+ memory B cells in infants living in a malaria-endemic region of Kenya. Malar J. 2011;10(1):362.
Moura RA, Weinmann P, Pereira PA, et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology. 2010;49(6):1082-1092.
Jacobsen MC, Thiébaut R, Fisher C, et al. Pediatric human immunodeficiency virus infection and circulating IgD + memory B cells. J Infect Dis. 2008;198(4):481-485.
Mackay F, Schneider P, Rennert P, Browning J. BAFF and april: a tutorial on B cell survival. Annu Rev Immunol. 2003;21(1):231-264.
Scholz JL, Crowley JE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci. 2008;105(40):15517-15522.
Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus. 2016;25(6):582-592.
Sellam J, Miceli-Richard C, Gottenberg JE, et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren’s syndrome and systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):790-797.
Nduati E, Gwela A, Karanja H, et al. The plasma concentration of the B cell activating factor is increased in children with acute malaria. J Infect Dis. 2011;204(6):962-970.
Montes CL, Acosta-Rodríguez EV, Mucci J, Zuniga EI, Campetella O, Gruppi A. A Trypanosoma cruzi antigen signals CD11b+ cells to secrete cytokines that promote polyclonal B cell proliferation and differentiation into antibody-secreting cells. Eur J Immunol. 2006;36(6):1474-1485.
Oliveira WN, Ribeiro LE, Schrieffer A, Machado P, Carvalho EM, Bacellar O. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. Cytokine. 2014;66(2):127-132.
Bacellar O, Lessa H, Schriefer A, et al. Up-Regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun. 2002;70(12):6734-6740.
Soni B, Saha B, Singh S. Cytokine systems cues governing IL6 signaling in leishmaniasis. Cytokine. 2018;106:169-175.
Pisetsky DS, Vrabie IA. Antibodies to DNA: infection or genetics? Lupus. 2009;18:1176-1180.